By MSB, page-310

The question posed to me by you is why I don’t believe what the company says can be taken as irrefutable and beyond question (“Madamswer, what part of my judgment do you not understand?”)

I have no doubt Messrs Simmons, Shpall, et al are eminently qualified in their field, as are all of the MSB executives.

But in relation to the specifics of your question to me, feel free to point out to me where the official company statement made in early 2010 of “…will enable us to provide a clear timetable to product commercialisation and early revenues (referring to bone marrow)” has become a reality?

And that’s my exact point in response to your query, which you have conveniently chosen to ignore, so I’ll paraphrase it for you again:

In the real world of commerce, industry and technology, things invariably happen that make the best intentioned plans of company managers not quite meet their own expectations, and often those plans – however well-considered and reasonable they are – come totally unstuck.
That’s just life.
Stuff happens.
It’s the nature of the beast.

Despite all the “excitement around the cord blood program” – and I don’t doubt for a minute that it is anything but exciting (despite your inexplicable assertion that I may be somehow “unsettled” by it) – it has not resulted in the “clear timeline to product commercialisation and early revenues” as was expected.

Similarly for the statements made years ago by the company relating to its programmes for Bone Repair, Diabetes, Cancer and Oseoarthritis, which have not lived up to management’s prevailing expectations back then, as I detailed in my earlier response.

And this is not just the sort of thing that happens with MSB (and will continue to happen, as sure as night follows), but it also happens to every single company (and will continue to do so), irrespective of how capable are the management teams involved.

Because of the vast array of imponderable factors in existence, forecasting the future is an imprecise activity, and if you think that every strategic objective that any CEO – including the MSB one – lays out should be simply be taken to be a given is, I think, somewhat naïve.

Which is why I don’t take each and every management utterance and articulation as given.
But, again, I’ll repeat it: if you are happy to do so, that’s a matter for you.



“I will take no notice of your views in any shape or form…”

Well, just stop asking me for my views in that case.


As for your question about RepliCart: “...and what are you inferring to ? "Please explain"
Well, if after 10 years of following this company and you don’t know what that is, then I don’t know how to help you other than to say that this was (is?) MSB’s trademarked product for prevention of osteoparthritis of the knee after knee trauma and reconstruction of the Anterior Cruciate Ligament, and was for which patients were recruited in 2010 for a Phase 2 trial. Ring any bells?